Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Valentino Ndaba | Photo Pexels
Dr Maramura
Dr Tafadzwa Maramura says she carved her path by remaining focused and resolute on her journey.

The African proverb ‘it takes a village to raise a child’ conveys the message that it requires many people to provide a safe and healthy environment for children. The village gives the child the security needed to develop and be able to realise their hopes and dreams. 

Dr Tafadzwa Maramura believes that the same applies vice versa. “It takes a good child to be raised by a village. You need to understand that the village can only do so much, the rest lies on your shoulders as the child,” she says.

The journey of a child raised by a village
The senior lecturer reflects on the journey that led her to serve in the Department of Public Administration and Management at the University of the Free State. At the age of three, she lost her father, who was an army general in Zimbabwe. Soon after, her academic journey would begin at a boarding school. Her widowed mother then moved her to a mission school due to financial constraints, seeing that she had two more children relying on her for survival. Since her father served in the government, she qualified for a state scholarship, which saw her launch her academic career in South Africa as an undergraduate student. 

“I came to South Africa in 2010 and pursued a Bachelor of Social Science degree in Development Economics at the University of Fort Hare. Once my honours were conferred, I acquired my master’s within a year. Thereafter, I enrolled at the North-West University, where I completed my PhD within two years.”

Dr Maramura was the Vice-Chancellor’s valedictorian for her bachelor, honours, and 
master’s degrees. Graduating cum laude was another way of ensuring that she pays it forward to the village that raised her. Not only was she funded by the Zimbabwean government, but she also received financial aid from South Africa throughout her studies. 

Once a child, now part of the village 
Today, as founder of a foundation based in Zimbabwe, she pays the fees of orphaned and disadvantaged primary school learners. “I wish everyone could adopt a child, pay their fees, buy their schoolbooks – because we only have each other, we do not have anyone else. That’s also part of what I call co-creating.”

The Brightest Young Minds in Africa alumna goes above and beyond focusing on academics, as she believes that “if you are the only one holding the light, everyone else will have to follow behind you to make sure that they can see ahead. However, if you share that light, then it means many more can see, therefore making it easier to solve societal challenges as a collective”.

She argues that the amount of money you spend on lunch could pay a child’s school fees for a term, and the cash that you use to buy a jacket or a pair of shoes, could cover a child’s fees for a month.
Making a difference in the lives of young children is her way of playing the role of the village now that she is an adult. “I make sure that wherever I am, I make an impact in the lives of others.”

Dr Maramura says she plans to make sure that life is better for the next young African female, by setting up a mentorship programme for the next generation of leaders. In addition to that, her goal is to become an associate professor, rise in academic rank, and develop a research unit that can speak to issues of sustainable service delivery.

On how to be a good child 
You do not need to be a figure of authority to make an impact. According to Dr Maramura, all you need is a desire to co-create, and making sure that the public is in a different place after you have left the relevant office you hold or the organisation you serve. “Make sure that you can co-exist, because humans don’t live in a vacuum, we exist among each other.”

Serving the people makes all the difference. She suggests that everyone asks themselves what they are doing for their community, class, or family. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept